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ittsburgh, Pennsylvania
trial fibrillation is the most common arrhythmia syndrome
n the U.S., affecting over 3 million people (1,2). Most cases
re sporadic, and risk factors include increasing age, hyper-
ension, cardiomyopathies of ischemic or nonischemic ori-
in, and valve diseases that alter atrial structure and elec-
rophysiological function. The morbidity of atrial fibrillation
omes from both the rapid irregularly irregular rhythm and
lood clots that lead to embolic strokes. Therapeutic options
or atrial fibrillation include rate control (beta-blockers,
a2 channel blockers, digoxin, or atrioventricular node
blation and ventricular pacing) used in conjunction with
ystemic anticoagulation (warfarin sodium) to prevent
trokes, or rhythm control (Class IA, IC, or III antiarrhyth-
ic drugs or surgical and catheter-based ablation). Several
andomized, controlled studies comparing rhythm and rate
ontrol have not shown a survival advantage for rhythm
ontrol (2–4). This may be caused by the limited effective-
ess of the currently available drugs in maintaining sinus
hythm and their proarrhythmic risks.
See page 1083
Abnormal focal impulse formation from automaticity
nd/or triggered activity and multiple-circuit reentry are the
ajor mechanisms responsible for the initiation and main-
enance of atrial fibrillation (5). Conditions that shorten
ction potential duration (APD), shorten the atrial effective
efractory period (AERP), or slow conduction velocity
romote atrial fibrillation. In addition, the fast heart rate in
trial fibrillation leads to a rapid decrease in APD and
ERP, a phenomenon called electrical remodeling that is
esponsible for the finding that atrial fibrillation begets atrial
brillation. As such, a large number of genes related to atrial
tructure and electrical function could theoretically contrib-
te to the arrhythmia.
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or theI
merican College of Cardiology.
From the Cardiovascular Institute, University of Pittsburgh, Pittsburgh, Pennsylvania.Atrial fibrillation has an inherited component (6). Using
andidate gene and linkage approaches, gain-of-function
utations in K channels have been identified in the rare
amilial forms of atrial fibrillation alone or in conjunction
ith other inherited arrhythmia syndromes (7–10). Germ
ine connexin 40 (Cx40) mutations and somatic Cx40
utations specific to atrial tissue have also been found in
ubjects with atrial fibrillation (11). Two additional loci for
trial fibrillation have been identified at chromosome
0q22–24 and 6q14–16 by linkage analysis in large families,
ut the genes and mutations responsible in these families
emain unknown (12,13). In addition, polymorphisms in
on channel (14,15) and non–ion channel genes such as
hose of the renin-angiotensin-aldosterone system (16) have
een associated with either lone atrial fibrillation or atrial
brillation caused by structural heart disease. Of note, a
enome-wide association study in an Icelandic population
ecently identified an additional locus at 4q25 for the
ommon forms of atrial fibrillation (17). The findings were
onfirmed in 3 replication cohorts of European descent and
n 1 of Chinese descent; the presence of the most predictive
ingle nucleotide polymorphism (rs2200733T, allele fre-
uency 0.1 to 0.2 in Europeans; 0.5 to 0.6 in Chinese) in the
inkage disequilibrium (LD) block increased the risk of
trial fibrillation by approximately 1.7, and the association
as stronger for younger subjects and for those with atrial
utter. The gene responsible for this association remains
nknown.
Many inherited cardiovascular diseases, including cardio-
yopathies and atrial fibrillation, are not apparent until
elatively advanced ages. This age-dependent penetrance
oses a challenge for linkage studies because identification
f sufficient living affected individuals for linkage is difficult,
any asymptomatic individuals may be gene carriers, and
poradic cases are more common in older individuals. The
se of endophenotypes, or hereditary characteristics that are
ssociated with the condition but are not a direct symptom
f that condition, may allow earlier identification of affected
ndividuals. For example, the presence of conduction disease
as been used to identify individuals with autosomal-
ominant forms of dilated cardiomyopathies before the
nset of left ventricular dysfunction (18).
In this issue of the Journal, Darbar et al. (19) studied a
oderate-sized family with lone atrial fibrillation inherited
n an autosomal-dominant manner and identified a novel
ocus at chromosome 5p15. They also showed that an
ndophenotype, signal-averaged P-wave duration correctly
dentified carriers of the disease locus and improved the
ogarithm of the odds score from 3.0 to 3.6. Of note, none
f the 5 known genes at that locus had mutations that could
xplain atrial fibrillation in this family.
To date, only mutations in ion channel genes have been
hown to cause familial atrial fibrillation, and the majority of
hese have been identified by the candidate gene approach.
n addition, although 2 other chromosomal loci were deter-
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March 18, 2008:1090–1 Editorial Commentined for lone atrial fibrillation 4 and 10 years ago, the
ausative genes have not been found as yet. Several factors
ake the genetics of atrial fibrillation difficult to study. First,
poradic atrial fibrillation is quite common in older individuals,
ncreasing the phenocopy rate and the potential for misclas-
ification of individuals as affected. Second, the penetrance
s age-dependent. Finally, the list of potential candidate
enes aside from ion channels is very long. In addition to all
enes expressed in the atrium related to structure and
lectrophysiology, a variety of other genes have been shown
o be associated with atrial fibrillation in transgenic mouse
odels (20,21).
The signal-averaged P-wave duration has been associated
ith atrial fibrillation in prior studies (20). The current
tudy supports its use for phenotypic characterization of
amilial atrial fibrillation, especially in young individuals
ho do not yet show the complete phenotype. Caution is
equired, however, in the interpretation of the results using
his test. Atrial fibrillation is genetically heterogeneous, and
here is no guarantee that all families will show similar
bnormalities in P-wave duration. In addition, individuals
ith sporadic atrial fibrillation in a family with inherited
brillation may also have abnormal P-wave duration, as a
esult of conditions such as structural heart disease. Thus,
lthough the use of the signal-averaged P-wave duration as
n endophenotype may increase the power to identify
inkage, it could also increase the likelihood of misclassifi-
ation of individuals when compared with the use of atrial
brillation alone in the linkage studies. As such, the use of
his and other endophenotypes has the potential to either
elp or hurt studies aimed at the ultimate identification of
he causative gene and mutation.
It is important to search for genes associated with both
amilial and nonfamilial forms of atrial fibrillation. These
enes, mutations, and polymorphisms may point toward novel
echanisms important for the maintenance of coordinated
trial rhythms and suggest new ways to prevent and/or treat the
ore common forms of this arrhythmia. As the population
ges, the prevalence and incidence of atrial fibrillation will
ontinue to increase. The study by Darbar et al. (19) and others
ike it may help to lessen the impact of this growing source of
ardiovascular morbidity and mortality.
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